p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy

B. Rao, S. Lain, A. M. Thompson

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Side effects of chemotherapy are a major impediment in the treatment of cancer. Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side effects of chemotherapy. Low, non-genotoxic doses of known p53 activators can be used to induce p53-dependent cell cycle arrest in normal cells bearing wild-type p53. This cytostatic effect of p53 can protect normal cells from the toxicity of S- or M-phase poisons. Here, we have reviewed existing cyclotherapy regimens using two well-known p53 activators, nutlin-3 and actinomycin D. We have highlighted an exemplar clinical perspective for cyclotherapy in breast cancer. The recent development of novel stapled peptides as activators of p53 without the corresponding cytotoxicity holds great promise for cyclotherapy to enhance the therapeutic window of existing chemotherapy drugs.British Journal of Cancer advance online publication, 14 November 2013; doi:10.1038/bjc.2013.702 www.bjcancer.com.
    Original languageEnglish
    Pages (from-to)2954-2958
    Number of pages5
    JournalBritish Journal of Cancer
    Volume109
    Issue number12
    DOIs
    Publication statusPublished - 10 Dec 2013

    Fingerprint Dive into the research topics of 'p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy'. Together they form a unique fingerprint.

  • Cite this